

Rational design, synthesis and molecular modeling studies of novel anti-oncological alkaloids against melanoma

Adel S. Girgis,*^a Siva S. Panda,^b Aladdin M. Srour,^c Hanaa Farag,^a Nasser S. M. Ismail,^d Mohamed Elgendi,^e Amal K. Abdel-Aziz^f and Alan R. Katritzky^{‡,b}

^aPesticide Chemistry Department, National Research Centre, Dokki, Giza 12622, Egypt.

^bCenter for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA.

^cTherapeutic Chemistry Department, National Research Centre, Dokki, Giza 12622, Egypt.

^dPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

^eDepartment of Experimental Oncology at the IFOM-IEO Campus, European Institute of Oncology, IEO, 20139 Milan, Italy.

^fPharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

*Corresponding authors: Adel S. Girgis, Fax: +33370931; Tel: +01220447199, e-mail: girgisas10@yahoo.com

†Professor Alan R. Katritzky passed away 10th February 2014.

Table S1 BMLR-QSAR two descriptor model for the GaLa carcinoma cell line active agents.

N=19, n=2, R ² =0.695, R ² _{cv} OO=0.570, R ² _{cv} MO=0.586, F=18.258, s ² =0.079					
Entry	ID	coefficient	s	t	Descriptor
1	0	18.986	3.118	6.090	Intercept
2	D ₁	1.955	0.354	5.522	HOMO energy
3	D ₂	-0.100	0.025	-3.989	Surface area for atom N

$\log(\text{IC}_{50}) = 18.986 + (1.955 \times D_1) - (0.100 \times D_2)$

Table S2 BMLR-QSAR two descriptor model for the LuPiCi carcinoma cell line active agents.

N=19, n=2, R ² =0.689, R ² _{cv} OO=0.564, R ² _{cv} MO=0.569, F=17.702, s ² =0.119					
Entry	ID	coefficient	s	t	Descriptor
1	0	22.669	3.809	5.952	Intercept
2	D ₁	2.397	0.433	5.542	HOMO energy
3	D ₂	-0.114	0.031	-3.720	Surface area for atom N

$\log(\text{IC}_{50}) = 22.669 + (2.397 \times D_1) - (0.114 \times D_2)$

Table S3 BMLR-QSAR two descriptor model for the LuCa carcinoma cell line active agents.

N=19, n=2, R ² =0.661, R ² _{cv} OO=0.540, R ² _{cv} MO=0.556, F=15.570, s ² =0.144					
Entry	ID	coefficient	s	t	Descriptor
1	0	23.802	4.228	5.629	Intercept
2	D ₁	2.344	0.464	5.050	HOMO energy
3	D ₂	-0.220	0.066	-3.307	HASA-2 (MOPAC PC)

log(IC₅₀) = 23.802 + (2.344 x D₁) - (0.220 x D₂)

Table S4 Molecular descriptor values presented in the 2D-QSAR models.

Entry	Compd.	Descriptors*								
		D ₁	D ₂	D ₃	D ₄	D ₅	D ₆	D ₇	D ₈	D ₉
1	20	14.377	0.969	0.096	0.000	0.812	8.347	-8.714	7.915	11.645
2	21	14.283	0.969	0.000	0.000	0.329	8.594	-8.842	3.044	9.206
3	22	14.394	0.969	0.190	0.014	0.620	8.337	-8.785	6.088	10.983
4	23	14.391	0.969	0.093	0.000	0.620	8.356	-8.788	6.088	10.983
5	24	14.320	0.969	0.000	0.000	0.068	8.452	-8.926	0.609	8.078
6	25	14.298	0.970	0.000	0.000	0.124	8.511	-8.771	1.218	8.214
7	26	14.312	0.969	0.000	0.000	0.272	8.420	-8.796	2.435	9.785
8	27	14.421	0.973	0.000	0.000	0.205	8.471	-8.714	1.827	9.686
9	28	14.426	0.972	0.000	0.000	0.179	8.481	-8.8	1.827	9.921
10	29	14.328	0.974	0.000	0.000	1.145	8.547	-8.769	9.742	11.880
11	30	14.406	0.969	0.000	0.000	0.192	8.423	-8.668	1.827	8.635
12	31	14.359	0.970	0.000	0.000	0.137	8.669	-8.826	1.218	9.005
13	32	14.401	0.970	0.000	0.000	0.055	8.566	-8.804	0.609	8.358
14	33	14.302	0.970	0.000	0.000	0.544	8.433	-8.777	4.871	10.191
15	34	14.317	0.970	0.000	0.000	0.943	7.983	-8.38	7.915	11.727
16	35	14.381	0.968	0.000	0.000	0.639	8.040	-8.336	5.480	8.687
17	36	14.407	0.970	0.050	0.000	0.192	8.673	-8.768	1.827	10.149
18	37	14.324	0.971	0.055	0.000	0.548	8.664	-8.951	5.480	12.283
19	38	14.433	0.969	0.000	0.000	0.483	7.936	-8.201	4.262	11.621



*D₁ = Min. total interaction for bond C-N, D₂ = Max. SIGMA-SIGMA bond order, D₃ = RPCS Relative positive charged SA (SAMPOS*RPCG) (Zefirov PC), D₄ = Relative number of Br atoms, D₅ = Charged surface area for atom N, D₆ = HOMO-LUMO energy gap, D₇ = HOMO energy, D₈ = Surface area for atom N, D₉ = HASA-2 (MOPAC PC).



Table S5 Descriptor of the BMLR-QSAR model for the mean IC₅₀ values of the three carcinoma cell lines (GaLa, LuPiCi and LuCa) active agents.



N=19, n=3, R ² =0.799, R ² _{cv} OO=0.688, R ² _{cv} MO=0.711, F=19.912, s ² =0.069					
Entry	ID	coefficient	s	t	Descriptor
1	0	95.981	42.546	2.256	Intercept
2	D ₁	7.609	1.312	5.802	Min. total interaction for bond C-N
3	D ₂	-210.000	42.570	-4.933	Max. SIGMA-SIGMA bond order
4	D ₃	-7.333	1.315	-5.575	RPCS Relative positive charged SA (SAMPOS*RPCG) (Zefirov PC)
$\log(\text{IC}_{50}) = 95.981 + (7.609 \times D_1) - (210.000 \times D_2) - (7.333 \times D_3)$					



Table S6 Observed and estimated/predicated values of the training set compounds **20-38** according to the BMLR-QSAR model due to mean IC₅₀ values of the three carcinoma cell lines (GaLa, LuPiCi and LuCa).



Entry	Compd.	Observed IC ₅₀ , μM	Estimated IC ₅₀ , μM	Error
1	20	28.62	17.64	10.98
2	21	4.64	11.83	-7.19
3	22	4.41	4.88	-0.47
4	23	24.63	23.78	0.85
5	24	37.94	30.43	7.51
6	25	24.80	13.95	10.85
7	26	22.43	19.82	2.61
8	27	28.59	28.93	-0.34
9	28	35.96	36.07	-0.11
10	29	3.91	2.53	1.38
11	30	29.21	111.75	-82.54
12	31	26.89	35.89	-9.00
13	32	62.35	88.75	-26.40
14	33	22.26	15.38	6.88
15	34	19.82	20.90	-1.08
16	35	314.77	118.63	196.14
17	36	33.61	29.50	4.11
18	37	2.88	5.69	-2.81
19	38	259.90	170.83	89.07




































Figure S1 GaLa carcinoma cell line 3D-pharmacophore mapped on the synthesized spiro-alkaloids **20-36**.




























Figure S2 LuPiCi carcinoma cell line 3D-pharmacophore mapped on the synthesized spiro-alkaloids **20-36**.


Compound 20




Compound 21







Compound 22







Compound 23






















Figure S3 LuCa carcinoma cell line 3D-pharmacophore mapped on the synthesized spiro-alkaloids **20-36**.




Figure S4 BMLR-QSAR model (two descriptors) plot of correlations representing the observed vs. predicted $\log(\text{IC}_{50})$ values for GaLa carcinoma cell line active agents.




Figure S5 BMLR-QSAR model (two descriptors) plot of correlations representing the observed vs. predicted $\log(\text{IC}_{50})$ values for LuPiCi carcinoma cell line active agents.




Figure S6 BMLR-QSAR model (two descriptors) plot of correlations representing the observed vs. predicted $\log(\text{IC}_{50})$ values for LuCa carcinoma cell line active agents.




Figure S7 BMLR-QSAR model (3 descriptors) plot of correlations representing the mean observed vs. predicted $\log(\text{IC}_{50})$ values of three carcinoma cell lines (GaLa, LuPiCi and LuCa) active agents (compound 11 is an outlier).